JP3247763B2 - キサンチン誘導体からなる血液循環の中断による神経損傷の治療用医薬 - Google Patents
キサンチン誘導体からなる血液循環の中断による神経損傷の治療用医薬Info
- Publication number
- JP3247763B2 JP3247763B2 JP11703393A JP11703393A JP3247763B2 JP 3247763 B2 JP3247763 B2 JP 3247763B2 JP 11703393 A JP11703393 A JP 11703393A JP 11703393 A JP11703393 A JP 11703393A JP 3247763 B2 JP3247763 B2 JP 3247763B2
- Authority
- JP
- Japan
- Prior art keywords
- blood circulation
- methyl
- mol
- interruption
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title claims description 19
- 230000017531 blood circulation Effects 0.000 title description 18
- 208000028389 Nerve injury Diseases 0.000 title description 8
- 230000008764 nerve damage Effects 0.000 title description 8
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 title description 6
- -1 4 -Oxo-3-methylpentyl Chemical group 0.000 claims description 7
- ZOJOOPXMAAZIGW-UHFFFAOYSA-N 2-[1-(ethoxymethyl)-3-methyl-2,6-dioxopurin-7-yl]-n,n-dimethylacetamide Chemical compound O=C1N(COCC)C(=O)N(C)C2=C1N(CC(=O)N(C)C)C=N2 ZOJOOPXMAAZIGW-UHFFFAOYSA-N 0.000 claims description 4
- JNIQKJZYFQPYBQ-UHFFFAOYSA-N 3-methyl-1-[3-(2-methyl-1,3-dioxolan-2-yl)butyl]-7-propylpurine-2,6-dione Chemical compound O=C1C=2N(CCC)C=NC=2N(C)C(=O)N1CCC(C)C1(C)OCCO1 JNIQKJZYFQPYBQ-UHFFFAOYSA-N 0.000 claims description 3
- AHLKSATYSUPWDB-UHFFFAOYSA-N 3-ethyl-7-(2-methoxyethyl)-1-(3-methyl-4-oxopentyl)purine-2,6-dione Chemical compound O=C1N(CCC(C)C(C)=O)C(=O)N(CC)C2=C1N(CCOC)C=N2 AHLKSATYSUPWDB-UHFFFAOYSA-N 0.000 claims description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 229910052757 nitrogen Inorganic materials 0.000 description 17
- 229910052739 hydrogen Inorganic materials 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 238000000921 elemental analysis Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 4
- MHNVSFOURBQRPK-UHFFFAOYSA-N 3-methyl-7-propylpurine-2,6-dione Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2CCC MHNVSFOURBQRPK-UHFFFAOYSA-N 0.000 description 4
- GMSNIKWWOQHZGF-UHFFFAOYSA-N 3-methyl-9H-xanthine Chemical compound O=C1NC(=O)N(C)C2=C1N=CN2 GMSNIKWWOQHZGF-UHFFFAOYSA-N 0.000 description 4
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 239000002168 alkylating agent Substances 0.000 description 4
- 229940100198 alkylating agent Drugs 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- XKEZKJHAYZEVNQ-UHFFFAOYSA-N 5-chloro-3-methylpentan-2-one Chemical compound CC(=O)C(C)CCCl XKEZKJHAYZEVNQ-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 206010053648 Vascular occlusion Diseases 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- SOOGLSUHNOETIG-UHFFFAOYSA-N 3-methyl-1,7-bis(2-oxo-2-piperazin-1-ylethyl)purine-2,6-dione Chemical compound C1=2C(=O)N(CC(=O)N3CCNCC3)C(=O)N(C)C=2N=CN1CC(=O)N1CCNCC1 SOOGLSUHNOETIG-UHFFFAOYSA-N 0.000 description 2
- PDDXCPHPYGJGIY-UHFFFAOYSA-N 3-methyl-1-(3-methyl-4-oxopentyl)-7-propylpurine-2,6-dione Chemical compound CN1C(=O)N(CCC(C)C(C)=O)C(=O)C2=C1N=CN2CCC PDDXCPHPYGJGIY-UHFFFAOYSA-N 0.000 description 2
- WQRASISGTROKJS-UHFFFAOYSA-N 3-methyl-1-(6-oxoheptyl)-7-propylpurine-2,6-dione Chemical compound CN1C(=O)N(CCCCCC(C)=O)C(=O)C2=C1N=CN2CCC WQRASISGTROKJS-UHFFFAOYSA-N 0.000 description 2
- CMDIDTNMHQUVPE-UHFFFAOYSA-N 6-chlorohexan-2-one Chemical compound CC(=O)CCCCCl CMDIDTNMHQUVPE-UHFFFAOYSA-N 0.000 description 2
- DEDHQVXKYCLMFM-UHFFFAOYSA-N 8-propyl-3,7-dihydropurine-2,6-dione Chemical compound N1C(=O)NC(=O)C2=C1N=C(CCC)N2 DEDHQVXKYCLMFM-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- HOSRTSNONHBDHP-UHFFFAOYSA-N ClCCC(C(C)=O)C.CN(C=O)C Chemical compound ClCCC(C(C)=O)C.CN(C=O)C HOSRTSNONHBDHP-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- CTOUWUYDDUSBQE-UHFFFAOYSA-N benzyl piperazine-1-carboxylate Chemical compound C1CNCCN1C(=O)OCC1=CC=CC=C1 CTOUWUYDDUSBQE-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229930188620 butyrolactone Natural products 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002026 chloroform extract Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000007631 vascular surgery Methods 0.000 description 2
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 description 1
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 1
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 1
- WYVZQGMSXUXEQW-UHFFFAOYSA-N 1,3-diethyl-7-(5-oxohexyl)purine-2,6-dione Chemical compound O=C1N(CC)C(=O)N(CC)C2=C1N(CCCCC(C)=O)C=N2 WYVZQGMSXUXEQW-UHFFFAOYSA-N 0.000 description 1
- GIMNFISWKTZFKJ-UHFFFAOYSA-N 1,3-diethyl-7h-purine-2,6-dione Chemical compound O=C1N(CC)C(=O)N(CC)C2=C1NC=N2 GIMNFISWKTZFKJ-UHFFFAOYSA-N 0.000 description 1
- LAOPFWOUVYJTAW-UHFFFAOYSA-N 1-(4-hydroxy-3-methylpentyl)-3-methyl-7-propylpurine-2,6-dione Chemical compound CN1C(=O)N(CCC(C)C(C)O)C(=O)C2=C1N=CN2CCC LAOPFWOUVYJTAW-UHFFFAOYSA-N 0.000 description 1
- JGOUYFFEQBNCJO-UHFFFAOYSA-N 1-chloro-3-ethyl-3-methylpentane Chemical compound CCC(C)(CC)CCCl JGOUYFFEQBNCJO-UHFFFAOYSA-N 0.000 description 1
- ONRMSHVZXZMZMP-UHFFFAOYSA-N 1-chloroheptan-4-one Chemical compound CCCC(=O)CCCCl ONRMSHVZXZMZMP-UHFFFAOYSA-N 0.000 description 1
- QQZOPKMRPOGIEB-UHFFFAOYSA-N 2-Oxohexane Chemical compound CCCCC(C)=O QQZOPKMRPOGIEB-UHFFFAOYSA-N 0.000 description 1
- RZDMKEUIFVPKFX-UHFFFAOYSA-N 2-[1-[carboxy-(4-phenylmethoxycarbonylpiperazin-1-yl)methyl]-3-methyl-2,6-dioxopurin-7-yl]-2-(4-phenylmethoxycarbonylpiperazin-1-yl)acetic acid Chemical compound C1=2C(=O)N(C(N3CCN(CC3)C(=O)OCC=3C=CC=CC=3)C(O)=O)C(=O)N(C)C=2N=CN1C(C(O)=O)N(CC1)CCN1C(=O)OCC1=CC=CC=C1 RZDMKEUIFVPKFX-UHFFFAOYSA-N 0.000 description 1
- XBPPLECAZBTMMK-UHFFFAOYSA-N 2-chloro-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CCl XBPPLECAZBTMMK-UHFFFAOYSA-N 0.000 description 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- DNGNNURPARKSKM-UHFFFAOYSA-N 3-ethyl-1-(5-oxohexyl)-7-propylpurine-2,6-dione Chemical compound CCN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CCC DNGNNURPARKSKM-UHFFFAOYSA-N 0.000 description 1
- NAQVWKXUNXUNOP-UHFFFAOYSA-N 3-ethyl-7-(2-methoxyethyl)purine-2,6-dione Chemical compound O=C1NC(=O)N(CC)C2=C1N(CCOC)C=N2 NAQVWKXUNXUNOP-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical group C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 description 1
- ZWXFUUDOIJKOOD-UHFFFAOYSA-N 7-chloroheptan-2-one Chemical compound CC(=O)CCCCCCl ZWXFUUDOIJKOOD-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- PAOHUVAJDNONKQ-UHFFFAOYSA-N CC1=NC=2NC(N(C(C2N1CCC)=O)CCCC(C)=O)=O Chemical compound CC1=NC=2NC(N(C(C2N1CCC)=O)CCCC(C)=O)=O PAOHUVAJDNONKQ-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003831 antifriction material Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- RQBLODLTRHWANL-UHFFFAOYSA-N benzyl 4-(2-chloroacetyl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)CCl)CCN1C(=O)OCC1=CC=CC=C1 RQBLODLTRHWANL-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- FCYRSDMGOLYDHL-UHFFFAOYSA-N chloromethoxyethane Chemical compound CCOCCl FCYRSDMGOLYDHL-UHFFFAOYSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 235000010855 food raising agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- CAGLFJFLAIZGFW-UHFFFAOYSA-N n,n-dimethyl-2-(3-methyl-2,6-dioxopurin-7-yl)acetamide Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2CC(=O)N(C)C CAGLFJFLAIZGFW-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 125000005188 oxoalkyl group Chemical group 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960005141 piperazine Drugs 0.000 description 1
- 229960003506 piperazine hexahydrate Drugs 0.000 description 1
- AVRVZRUEXIEGMP-UHFFFAOYSA-N piperazine;hexahydrate Chemical compound O.O.O.O.O.O.C1CNCCN1 AVRVZRUEXIEGMP-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- IUYQIJQHYDZUDF-UHFFFAOYSA-N pyrazolo[3,4-d]pyrimidin-4-one Chemical compound O=C1N=CN=C2N=NC=C12 IUYQIJQHYDZUDF-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4216711:6 | 1992-05-20 | ||
| DE4216711 | 1992-05-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0656833A JPH0656833A (ja) | 1994-03-01 |
| JP3247763B2 true JP3247763B2 (ja) | 2002-01-21 |
Family
ID=6459346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP11703393A Expired - Fee Related JP3247763B2 (ja) | 1992-05-20 | 1993-05-19 | キサンチン誘導体からなる血液循環の中断による神経損傷の治療用医薬 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US5922868A (en:Method) |
| EP (1) | EP0570831A2 (en:Method) |
| JP (1) | JP3247763B2 (en:Method) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5506518B2 (ja) * | 2010-04-13 | 2014-05-28 | アキレス株式会社 | 光学式マウス対応マット |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1211333A (fr) * | 1955-10-19 | 1960-03-15 | Boehringer Sohn Ingelheim | Perfectionnements apportés aux procédés pour fabriquer des oxyalcoylxanthines |
| US3737433A (en) * | 1964-09-05 | 1973-06-05 | Albert Ag Chem Werke | Certain oxoalkyldimethylxanthines |
| DE2335170C2 (de) * | 1973-07-11 | 1989-07-20 | Hoechst Ag, 6230 Frankfurt | 1,3-Dialkyl-7-(hydroxyalkyl)-xanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| DE2234202A1 (de) * | 1972-07-12 | 1974-01-24 | Albert Ag Chem Werke | Verfahren zur herstellung von oxoalkylxanthinen |
| BE795345A (fr) * | 1972-02-19 | 1973-08-13 | Albert Ag Chem Werke | MEDICAMENT UTILE NOTAMMENT POUR L'IRRIGATION CEREBRALE, PROCEDE DE PREPARATION DE SES MATIERES ACTIVES ET CES MATIERES ElLES-MEMES |
| DE2330741A1 (de) * | 1973-06-16 | 1975-01-09 | Albert Ag Chem Werke | Verfahren zur herstellung von oxoalkylxanthinen |
| DE2330742C2 (de) * | 1973-06-16 | 1982-07-29 | Hoechst Ag, 6000 Frankfurt | 1-(Oxoalkyl)-3-methyl-7-alkylxanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| DE2462367A1 (de) * | 1974-01-22 | 1976-11-11 | Wuelfing J A Fa | 7-(oxoalkyl)-1,3-dialkylxanthine enthaltende arzneimittelzubereitungen |
| CH608236A5 (en:Method) * | 1974-01-22 | 1978-12-29 | Wuelfing J A Fa | |
| CH622519A5 (en) * | 1974-07-05 | 1981-04-15 | Hoechst Ag | Process for the preparation of hydroxyalkylxanthines |
| DE2432702C2 (de) * | 1974-07-08 | 1983-01-20 | Hoechst Ag, 6000 Frankfurt | Verfahren zur Herstellung von Hydroxyalkylxanthinen |
| LU71047A1 (en:Method) * | 1974-10-03 | 1975-06-24 | ||
| LU71048A1 (en:Method) * | 1974-10-03 | 1975-04-17 | ||
| DE2457666A1 (de) * | 1974-12-06 | 1976-06-10 | Hoechst Ag | Arzneimittel, verfahren zur herstellung von dafuer geeigneten wirkstoffen und diese oxoalkyl-dialkyl-xanthine |
| DE2507555A1 (de) * | 1975-02-21 | 1976-09-02 | Wuelfing J A Fa | 7-(oxoalkyl)-1,3-dialkylxanthine, verfahren zu ihrer herstellung und diese verbindung enthaltende arzneimittel |
| AT339918B (de) * | 1975-07-04 | 1977-11-10 | Hoechst Ag | Verfahren zur herstellung von mono- (hydroxyalkyl) -di-alkylxanthinen |
| EP0005015B1 (en) * | 1978-04-22 | 1986-10-29 | BEECHAM - WUELFING GmbH & Co. KG | Use of a xanthine derivate in the manufacture of a medicament |
| DE2929596A1 (de) * | 1979-07-21 | 1981-02-05 | Hoechst Ag | Verfahren zur herstellung von oxoalkyl-xanthinen |
| EP0157098A1 (en) * | 1980-06-21 | 1985-10-09 | Beecham Wuelfing GmbH & Co KG | Xanthine derivatives, pharmaceuticals compositions containing them and a process for their preparation |
| DE3525801A1 (de) * | 1985-07-19 | 1987-01-22 | Hoechst Ag | Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung |
| GB8601371D0 (en) * | 1986-01-21 | 1986-02-26 | Beecham Group Plc | Compounds |
| GB8621870D0 (en) * | 1986-09-11 | 1986-10-15 | Beecham Group Plc | Active compounds |
| JPS63225317A (ja) * | 1986-10-06 | 1988-09-20 | Hoechst Japan Kk | 抗消化性潰瘍剤 |
| CH670090A5 (en:Method) * | 1986-10-27 | 1989-05-12 | Nestle Sa | |
| JP2661666B2 (ja) * | 1988-02-19 | 1997-10-08 | ヘキスト薬品工業株式会社 | 抗消化性潰瘍剤 |
| DD298051A5 (de) * | 1989-08-16 | 1992-02-06 | ��@���������@�������k�� | Verfahren zur herstellung eines therapeutischen agens zur behandlung von verdauungskrankheiten |
| JPH03167186A (ja) * | 1989-11-24 | 1991-07-19 | Hokuriku Seiyaku Co Ltd | キサンチン誘導体及びその用途 |
| DE3942872A1 (de) * | 1989-12-23 | 1991-06-27 | Hoechst Ag | Verfahren zur enantioselektiven darstellung von ((omega)-1)-hydroxyalkylxanthinen |
| MX9203323A (es) * | 1991-07-11 | 1994-07-29 | Hoechst Ag | El empleo de derivados de xantina para el tratamiento de lesiones secundarias de las celulas nerviosas y trastornos funcionales despues de traumas craneo-cerebrales. |
-
1993
- 1993-05-12 EP EP93107735A patent/EP0570831A2/de not_active Withdrawn
- 1993-05-19 JP JP11703393A patent/JP3247763B2/ja not_active Expired - Fee Related
-
1995
- 1995-12-22 US US08/576,936 patent/US5922868A/en not_active Expired - Lifetime
Non-Patent Citations (5)
| Title |
|---|
| Ｃｈｅｍｉｃａｌ Ａｂｓｔｒａｃｔｓ，Ｖｏｌ．５１（１９５７）ａｂｓｔｒａｃｔ ｎｏ．１１９５ｅ |
| Ｃｈｅｍｉｃａｌ Ａｂｓｔｒａｃｔｓ，Ｖｏｌ．５２（１９８５）ａｂｓｔｒａｃｔ ｎｏ．１２８７４ｈ |
| Ｃｈｅｍｉｃａｌ Ａｂｓｔｒａｃｔｓ，Ｖｏｌ．６５（１９６６）ａｂｓｔｒａｃｔ ｎｏ．８９１０ｄ |
| ＮＥＵＲＯＬＯＧＹ，Ｖｏｌ．２７（Ｊａｎｕａｒｙ １９７７）ｐ．７７−８４ |
| Ｐｈａｒｍａｚｉｅ，Ｖｏｌ．２８，Ｎｏ．５（１９７３）ｐ．３００−３０３ |
Also Published As
| Publication number | Publication date |
|---|---|
| US5922868A (en) | 1999-07-13 |
| JPH0656833A (ja) | 1994-03-01 |
| EP0570831A2 (de) | 1993-11-24 |
| EP0570831A3 (en:Method) | 1994-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU1486060A3 (ru) | Способ получения производных 2-индолинона | |
| JPS61263917A (ja) | 脳機能正常化剤 | |
| KR20220046511A (ko) | 염증반응을 예방 치료하는 뉴클레오시드류 유도체 및 그 응용 | |
| SU1470190A3 (ru) | Способ получени 6-/4 @ -ацетил-2-метилимидазол-1-ил/-8-метил-2-/1Н/-карбостирила | |
| EP1144410A2 (de) | Verwendung von imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen als arzneimittel | |
| JP3119738B2 (ja) | Ｎ−フェニル−２−シアノ−３−ヒドロキシクロトンアミド誘導体および免疫調整性を有する医薬品としてのその使用 | |
| CN114456163A (zh) | 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用 | |
| FI90545C (fi) | Menetelmä terapeuttisesti aktiivisten 2,2-dimetyylikromeenijohdannaisten valmistamiseksi | |
| EP0682947A1 (en) | Medicament for therapeutic and prophylactic treatment of diseases caused by smooth muscle cell hyperplasia | |
| JP3247763B2 (ja) | キサンチン誘導体からなる血液循環の中断による神経損傷の治療用医薬 | |
| EP0356230B1 (en) | Quinoline compound | |
| EP0994113A2 (en) | 7-Aminopyrido(2,3-d)-pyrimidine derivatives for treatment of bronchial asthma | |
| US4851414A (en) | Anti-dementia agent | |
| US4992457A (en) | Pharmacologically active cholinergic compositions, and methods for making same and use thereof in treating disease | |
| JPH0320394B2 (en:Method) | ||
| NO312400B1 (no) | Anvendelse av teofyllinderivater for behandling og profylakse av sjokktilstander, nye xantanforbindelser og deres fremstilling | |
| TWI225397B (en) | Uses of thaliporphine or its derivatives in treatment of cardiac diseases and preparation of the same | |
| US4128555A (en) | 3-Phenoxypyridine monosulfate and a method for its production | |
| US4571403A (en) | Antianginal medicated compound | |
| WO1988007043A1 (en) | Pharmacologically active cholinergic compositions, and methods for making same and use thereof in treating disease | |
| JP3553158B2 (ja) | ピリダジノインドール誘導体 | |
| EP1071427B1 (en) | Intermittent claudication therapeutic drugs comprising pyrroloazepines | |
| US4224335A (en) | Tetrahydrocarbazoles and their use | |
| US4678796A (en) | 2-alkylidene derivatives of 1,2,3,4-tetrahydropyridine-2,5-pyridine carboxylic acid dialkyl esters useful for treatment of cardiovascular disorders | |
| JP2006316064A (ja) | ３（２ｈ）−ピリダジノン誘導体及びこれら化合物の使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071102 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081102 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091102 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091102 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101102 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111102 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121102 Year of fee payment: 11 |
|
| LAPS | Cancellation because of no payment of annual fees |